Company Profile
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. The Company's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the acute treatment of agitation associated with Alzheimer’s disease and as an adjunctive treatment for Major Depressive Disorder, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.
Corporate
BioXcel Therapeutics
Erik Kopp
T: 203-494-7062
Ekopp@bioxceltherapeutics.com
Investor
BioXcel Therapeutics
Brennan Doyle
T: 475-355-8462
Bdoyle@bioxceltherapeutics.com
Media
Russo Partners
David Schull or Scott Stachowiak
T: 858-717-2310
David.schull@russopartnersllc.com
Scott.stachowiak@russopartnersllc.com
Transfer Agent
American Stock Transfer and Trust
Auditor
Ernst & Young LLP
Legal Counsel
Latham & Watkins LLP
Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Stock Chart
Featured News
Events
SEC Filings
Filing date | Form | Description | Filing Group |
---|---|---|---|
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
|
144 | Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing |
Other
|
|
DEF 14A | Official notification to shareholders of matters to be brought to a vote ("Proxy") |
Proxy Filings
|
|
144/A | Amendment to a previously filed 144 |
Other
|
|
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
Data Provided by Refinitiv. Minimum 15 minutes delayed.